Natixis Advisors LLC Has $907,000 Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Natixis Advisors LLC raised its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 37.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 45,637 shares of the biopharmaceutical company’s stock after purchasing an additional 12,491 shares during the quarter. Natixis Advisors LLC’s holdings in Catalyst Pharmaceuticals were worth $907,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in CPRX. Susquehanna Fundamental Investments LLC acquired a new position in shares of Catalyst Pharmaceuticals in the 2nd quarter worth approximately $258,000. Integral Health Asset Management LLC acquired a new position in shares of Catalyst Pharmaceuticals in the 2nd quarter worth approximately $4,260,000. GSA Capital Partners LLP acquired a new position in shares of Catalyst Pharmaceuticals in the 3rd quarter worth approximately $625,000. Vanguard Group Inc. boosted its holdings in shares of Catalyst Pharmaceuticals by 12.1% in the 1st quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock worth $127,212,000 after acquiring an additional 860,244 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 146.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 366,444 shares of the biopharmaceutical company’s stock worth $7,285,000 after acquiring an additional 217,956 shares in the last quarter. 79.22% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on CPRX. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Stephens initiated coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an “overweight” rating and a $35.00 price objective for the company. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Truist Financial boosted their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Finally, Citigroup boosted their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $31.14.

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock opened at $22.34 on Thursday. The firm has a fifty day moving average of $21.17 and a two-hundred day moving average of $18.67. The stock has a market capitalization of $2.66 billion, a price-to-earnings ratio of 18.58, a PEG ratio of 3.26 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a 52 week low of $13.00 and a 52 week high of $24.27.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.